Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,777.20
(
-0.08%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.42
(
3.60%
)
Bitcoin
70,427.84
(
-1.14%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 2726

Tuesday, 06/19/2007 7:54:51 AM

Tuesday, June 19, 2007 7:54:51 AM

Post# of 19309
ZGEN, Bayer Ink Deal for Recombinant Thrombin:
#msg-20562195.

Note: this is thrombin, not antithrombin. The relevance of this deal for GTC is indirect: the deal shows that Bayer thinks recombinant thrombin will be a commercial success due to its inherent safety advantage despite the fact that plasma-derived thrombin is widely available.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now